PRESS RELEASE
News
-
-
-
PRESS RELEASE
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Mainz Biomed and Liquid Biosciences make groundbreaking discovery of mRNA biomarkers for blood-based detection of pancreatic cancer, achieving transformative sensitivity of 95% and specificity of 98% -
PRESS RELEASE
Healthcare Specialist SHS Capital, together with its co-investors, sells Selfapy GmbH to MEDICE - The Health Family
SHS Capital and co-investors sell Selfapy GmbH to MEDICE - The Health Family, a step towards clinically validated healthcare solutions integrating pharmaceuticals and digital concepts -
PRESS RELEASE
Amoéba participe à la 3ème édition du Retail Day organisée par Euroland Corporate et Bourse Direct le jeudi 20 mars 2025
Amoéba, greentech spécialisée dans les solutions microbiologiques naturelles, participe à la 3ème édition du Retail Day pour présenter sa vision et stratégie de développement -
PRESS RELEASE
Vox Royalty Provides Development Updates and Approval of 2025 Share Repurchase Program
Vox Royalty Corp. provides updates on mining royalty partners Black Cat Syndicate Limited, Orla Mining Ltd., and Galway Metals Inc. Recent developments include new acquisitions and progress towards production in Western Australia, Nevada, and Quebec -
PRESS RELEASE
bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne
bonyf secures EU Patent, pending US patent, for PerioTabs® & PerioCream, set to launch at IDS Cologne in March 2025. Products aim to revolutionize dental care practices globally -
-
PRESS RELEASE
REPLY: The Board of Directors approved the draft financial statements for the year 2024
Reply S.p.A. Board of Directors approves draft financial statements for 2024, proposing dividend distribution of €1.15 per share. Positive financial indicators with increased turnover and net profit -
PRESS RELEASE
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Xenetic Biosciences presents promising findings on combining DNase I with CAR T cells to enhance cancer treatment strategies at the SITC Spring Scientific 2025 Cell Therapy Meeting
